161 related articles for article (PubMed ID: 25112687)
21. Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA).
Hijjawi MS; Abutayeh RF; Taha MO
Molecules; 2020 Dec; 25(24):. PubMed ID: 33353031
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold.
Zhou S; Zhou L; Cui R; Tian Y; Li X; You R; Zhong L
Comb Chem High Throughput Screen; 2016; 19(1):73-96. PubMed ID: 26632441
[TBL] [Abstract][Full Text] [Related]
23. 3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors.
Lan P; Chen WN; Sun PH; Chen WM
J Mol Model; 2011 May; 17(5):1191-205. PubMed ID: 20697761
[TBL] [Abstract][Full Text] [Related]
24. Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.
Sarvagalla S; Singh VK; Ke YY; Shiao HY; Lin WH; Hsieh HP; Hsu JT; Coumar MS
J Comput Aided Mol Des; 2015 Jan; 29(1):89-100. PubMed ID: 25344840
[TBL] [Abstract][Full Text] [Related]
25. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
26. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
27. Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies.
Kumar A; Rathi E; Kini SG
J Biomol Struct Dyn; 2020 Apr; 38(7):2156-2170. PubMed ID: 31179854
[TBL] [Abstract][Full Text] [Related]
28. General Ser/Thr Kinases Pharmacophore Approach for Selective Kinase Inhibitors Search as Exemplified by Design of Potent and Selective Aurora A Inhibitors.
Vasilevich NI; Aksenova EA; Kazyulkin DN; Afanasyev II
Chem Biol Drug Des; 2016 Jul; 88(1):54-65. PubMed ID: 26825399
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors.
Teli MK; Rajanikant GK
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):558-70. PubMed ID: 21851209
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
Dev S; Dhaneshwar SR; Mathew B
Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
[TBL] [Abstract][Full Text] [Related]
32. Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment.
Rai A; Raj V; Aboumanei MH; Singh AK; Keshari AK; Verma SP; Saha S
Comb Chem High Throughput Screen; 2017; 20(8):658-674. PubMed ID: 28486913
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies.
Zhang W; Qiu KX; Yu F; Xie XG; Zhang SQ; Chen YJ; Xie HD
Comput Biol Chem; 2017 Oct; 70():186-190. PubMed ID: 28892749
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.
Chang CF; Lin WH; Ke YY; Lin YS; Wang WC; Chen CH; Kuo PC; Hsu JTA; Uang BJ; Hsieh HP
Eur J Med Chem; 2016 Nov; 124():186-199. PubMed ID: 27573544
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic insights into mode of action of novel natural cathepsin L inhibitors.
Tyagi C; Grover S; Dhanjal J; Goyal S; Goyal M; Grover A
BMC Genomics; 2013; 14 Suppl 8(Suppl 8):S10. PubMed ID: 24564425
[TBL] [Abstract][Full Text] [Related]
37. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
Shah BM; Modi P; Trivedi P
J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
[TBL] [Abstract][Full Text] [Related]
38. Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.
Lan P; Chen WN; Chen WM
Eur J Med Chem; 2011 Jan; 46(1):77-94. PubMed ID: 21093113
[TBL] [Abstract][Full Text] [Related]
39. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
40. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
